Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 496 Results

Page 45 of 50« First «...10 20 30...43 444546 47...50...»Last »

February 18, 2014

DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease

January 30, 2014

DBV Technologies Reports Full Year 2013 Topline Financial Results

December 17, 2013

DBV provides 2013 year-end summary and news flow guidance for 2014

December 13, 2013

Dr. Hugh Sampson presents Epicutaneous Immunotherapy for Food Allergy at the World Allergy Organization Conference

November 26, 2013

DBV Technologies Enters into Collaboration Agreement with BioNetAsia and University of Geneva on Whooping Cough Booster Vaccine

November 14, 2013

DBV Technologies announces the completion of a €29.9m private placement with a majority placed with US investors

October 24, 2013

NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies’ Viaskin^® Peanut in the treatment of peanut allergy

October 22, 2013

DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin^® for Refractory Hemophilia A Disease

October 18, 2013

Stallergenes and DBV Technologies Announce Respiratory Allergy Research and Development Collaboration for Birch Pollen

October 15, 2013

DBV Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin^® Peanut

Page 45 of 50« First «...10 20 30...43 444546 47...50...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top